We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026

X-Ray Imaging System Enables Scientists to See in Real Time How Effective Treatments are for Cystic Fibrosis

By HospiMedica International staff writers
Posted on 25 Aug 2014
A new imaging approach allows researchers to monitor the effectiveness of a treatment for the life-threatening genetic disorder. More...


Cystic fibrosis affects many of the body’s systems, but most severely the lungs, and currently it can take several months to measure how effective treatment is for the early-fatal lung disease.

Dr. Kaye Morgan, from Monash University (Melbourne; VIC, Australia), and lead researcher of the study, reported that the new X-ray imaging strategy allows researchers to visualize soft tissue structures, for example, the airways, brain, and lungs, which are effectively hidden in standard X-ray images. “At the moment we typically need to wait for a cystic fibrosis treatment to have an effect on lung health, measured by either a lung CT [computed tomography] scan or breath measurement, to see how effective that treatment is,” Dr. Morgan said. “However the new imaging technique allows us for the first time to noninvasively see how the treatment is working ‘live’ on the airway surface.”

Dr. Morgan noted that this X-ray imaging method would enable clinicians and researchers to measure how effective treatments are, and progress new treatments to the clinic at a much quicker rate, a key goal of the investigators. “Because we will be able to see how effectively treatments are working straight away, we’ll be able to develop new treatments a lot more quickly, and help better treat people with cystic fibrosis,” Dr. Morgan said.

Dr. Morgan noted that the new imaging technology, which was developed using a synchrotron X-ray source, may also create new avenues for assessing how effective treatments were for other lung, heart, and brain diseases.

The study’s findings were published August 15, 2014, in the American Journal of Respiratory and Critical Care Medicine.

Related Links:

Monash University



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Hypodermic Syringe
SurTract™ Safety Syringe
Hybrid Arch Device
Neo EDE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image Credit: 123RF

Existing Cardiovascular Risk Calculators Predict Several Common Cancers

Cardiovascular risk calculators are embedded in primary and secondary care to estimate 10‑year risk of heart attack or stroke from factors such as age, body mass index, and smoking. Many of these same... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.